Sareina Wu
Chief Executive Officer Genome Frontier
Seminars
Wednesday 25th February 2026
Use of Quantum Engine to Develop Multiplex Dual-Targeting CD19/CD20 CAR-T (SCM) Therapy for B-Cell Malignancies
5:00 pm
- Introduce Quantum Engine for non-viral gene therapy
- Describe the benefits of dual-targeting CD19/CD20 T(SCM) cells to overcome antigen escape and improve response durability
- Present preliminary findings from a Phase I open-label trial of GF-CART01 for relapsed or refractory B-cell haematologic cancers
New Data
